The future of direct-to-consumer clinical genetic tests
- 1 June 2011
- journal article
- viewpoint
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 12 (7) , 511-515
Abstract
In light of the meeting of the US Food and Drug Administration (FDA) in March 2011 to discuss the regulation of clinical direct-to-consumer (DTC) genetic tests, we have invited five experts to consider the best means of overseeing the ordering and interpretation of these tests. Should these tests be regulated? If so, who, if anyone, should communicate results to consumers?Keywords
This publication has 19 references indexed in Scilit:
- Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease RiskNew England Journal of Medicine, 2011
- Effects of communicating DNA-based disease risk estimates on risk-reducing behavioursCochrane Database of Systematic Reviews, 2010
- “I know what you told me, but this is what I think:” Perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimateGenetics in Medicine, 2010
- Genetic Testing For Alzheimer’s And Long-Term Care InsuranceHealth Affairs, 2010
- Direct to consumer genetic testing: Avoiding a culture warGenetics in Medicine, 2009
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseNew England Journal of Medicine, 2009
- Developing the Blueprint for a Genetic Testing RegistryPublic Health Genomics, 2009
- An Unwelcome Side Effect of Direct-to-Consumer Personal Genome TestingJAMA, 2008
- Genomewide Association Analysis of Coronary Artery DiseaseNew England Journal of Medicine, 2007
- A Coronary Heart Disease Risk Score Based on Patient-Reported InformationThe American Journal of Cardiology, 2007